Applied Therapeutics Inc $ 21.83 -0.06 (-0.27%)
Volume:
58,733
Avg Vol (1m):
126,444
Market Cap $:
490.92 Mil
Enterprise Value $:
378.34 Mil
P/E (TTM):
0.00
P/B:
4.76
Current and historical daily P/E ratio for APLT (Applied Therapeutics Inc) from 2019 to Jan 20 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Applied Therapeutics stock (APLT) PE ratio as of Jan 20 2021 is 0.
More Details
Applied Therapeutics PE Ratio (TTM) Chart
EMBED
Applied Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 441
- 1
- 2
- 3
- 4
- 5
| Applied Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-01-20 | 0.0 | 2020-11-17 | 0.0 |
| 2021-01-19 | 0.0 | 2020-11-16 | 0.0 |
| 2021-01-15 | 0.0 | 2020-11-13 | 0.0 |
| 2021-01-14 | 0.0 | 2020-11-12 | 0.0 |
| 2021-01-13 | 0.0 | 2020-11-11 | 0.0 |
| 2021-01-12 | 0.0 | 2020-11-10 | 0.0 |
| 2021-01-11 | 0.0 | 2020-11-09 | 0.0 |
| 2021-01-08 | 0.0 | 2020-11-06 | 0.0 |
| 2021-01-07 | 0.0 | 2020-11-05 | 0.0 |
| 2021-01-06 | 0.0 | 2020-11-04 | 0.0 |
| 2021-01-05 | 0.0 | 2020-11-03 | 0.0 |
| 2021-01-04 | 0.0 | 2020-11-02 | 0.0 |
| 2021-01-01 | 0.0 | 2020-10-30 | 0.0 |
| 2020-12-31 | 0.0 | 2020-10-29 | 0.0 |
| 2020-12-30 | 0.0 | 2020-10-28 | 0.0 |
| 2020-12-29 | 0.0 | 2020-10-27 | 0.0 |
| 2020-12-28 | 0.0 | 2020-10-26 | 0.0 |
| 2020-12-25 | 0.0 | 2020-10-23 | 0.0 |
| 2020-12-24 | 0.0 | 2020-10-22 | 0.0 |
| 2020-12-23 | 0.0 | 2020-10-21 | 0.0 |
| 2020-12-22 | 0.0 | 2020-10-20 | 0.0 |
| 2020-12-21 | 0.0 | 2020-10-19 | 0.0 |
| 2020-12-18 | 0.0 | 2020-10-16 | 0.0 |
| 2020-12-17 | 0.0 | 2020-10-15 | 0.0 |
| 2020-12-16 | 0.0 | 2020-10-14 | 0.0 |
| 2020-12-15 | 0.0 | 2020-10-13 | 0.0 |
| 2020-12-14 | 0.0 | 2020-10-12 | 0.0 |
| 2020-12-11 | 0.0 | 2020-10-09 | 0.0 |
| 2020-12-10 | 0.0 | 2020-10-08 | 0.0 |
| 2020-12-09 | 0.0 | 2020-10-07 | 0.0 |
| 2020-12-08 | 0.0 | 2020-10-06 | 0.0 |
| 2020-12-07 | 0.0 | 2020-10-05 | 0.0 |
| 2020-12-04 | 0.0 | 2020-10-02 | 0.0 |
| 2020-12-03 | 0.0 | 2020-10-01 | 0.0 |
| 2020-12-02 | 0.0 | 2020-09-30 | 0.0 |
| 2020-12-01 | 0.0 | 2020-09-29 | 0.0 |
| 2020-11-30 | 0.0 | 2020-09-28 | 0.0 |
| 2020-11-27 | 0.0 | 2020-09-25 | 0.0 |
| 2020-11-26 | 0.0 | 2020-09-24 | 0.0 |
| 2020-11-25 | 0.0 | 2020-09-23 | 0.0 |
| 2020-11-24 | 0.0 | 2020-09-22 | 0.0 |
| 2020-11-23 | 0.0 | 2020-09-21 | 0.0 |
| 2020-11-20 | 0.0 | 2020-09-18 | 0.0 |
| 2020-11-19 | 0.0 | 2020-09-17 | 0.0 |
| 2020-11-18 | 0.0 | 2020-09-16 | 0.0 |
Applied Therapeutics PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NAS:ENTA
NAS:SRNE
NAS:ARCT
NAS:PASG
NYSE:MYOV
NAS:AIMT
NAS:ODT
NAS:RCKT
NAS:ESPR
NAS:ARQT
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
Address
545 Fifth Avenue, Suite 1400, New York, NY, USA, 10173
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.